<DOC>
	<DOCNO>NCT01821248</DOCNO>
	<brief_summary>To evaluate efficacy safety preoperative chemotherapy Gemcitabine/ Cisplatin /S-1 biliary tract cancer lymph node metastasis FDG-PET .</brief_summary>
	<brief_title>A Phase II Trial Preoperative Chemotherapy Biliary Tract Cancer ( BTC ) With Node Metastasis</brief_title>
	<detailed_description>Biliary tract cancer one lethal malignancy worldwide , surgery represent potentially curative treatment disease . However , many patient diagnose far advanced stage , late curative resection , even surgery perform , likelihood relapse high . Lymph node metastasis powerful prognostic factor biliary tract cancer , make accurate preoperative assessment lymph node metastasis important indication resection . However , diagnostic accuracy , sensitivity , specificity conventional imaging technique , include compute tomography ( CT ) magnetic resonance imaging ( MRI ) , seem insufficient accurate detection lymph node metastasis . Previously , investigator report FDG-PET useful prediction lymph node metastasis . On hand , gemcitabine widely use treat patient unresectable recurrent biliary tract cancer . In Advanced Biliary tract Cancer ( ABC ) -02 study , first prospective multicenter phase III study field , combination gemcitabine/cisplatin compare gemcitabine monotherapy find combination regimen significantly prolong Median Survival Time ( MST ) ( 8.1 11.7 month ; P &lt; 0.001 ) . Gemcitabine/cisplatin combination therapy consider standard regimen advance biliary tract cancer . S-1 oral fluoropyrimidine prodrug confirm efficacy various solid tumor , alone combination cytotoxic drug . S-1 monotherapy yield good result advance biliary tract cancer gemcitabine/S-1 combination therapy yield promising result acceptable toxicity level patient advance biliary tract cancer . Furthermore , investigator report safety efficacy add S-1 gemcitabine/cisplatin combination regimen ( GCS ) advance biliary tract cancer . In study , investigator evaluate efficacy safety preoperative chemotherapy Gemcitabine/ Cisplatin /S-1 biliary tract cancer lymph node metastasis FDG-PET</detailed_description>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients radiologically proven biliary tract cancer . 2 . No extrahepatic disease . 3 . No prior therapy . 4 . The function liver keep satisfied hepatectomy . 5 . No chronic liver damage . 6 . Patients age 20 year . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 8 . Sufficient organ function ( neutrophil count &gt; =1,500/mm3 platelet count &gt; =100,000/mm3 , Hemoglobin &gt; =9.0g/dL , Aspartate transaminase ( AST ) /alanine aminotransferase ( ALT ) &lt; =150 IU/L , total bilirubin &lt; =1.5 mg/dL , creatinine &lt; =1.2 mg/dL , creatinine clearance &gt; =60 mL/min ) 9.Patients obtain write informed consent . 1 . Massive abdominal effusion require treatment . 2 . Active concomitant malignancy . 3 . The case suspect infection . 4 . Patients water solubility diarrhea . 5 . Mental disease psychotic manifestation . 6 . Under continuous steroid therapy . 7 . Patients acute myocardial infarction . 8 . Patients severe complication . 9 . Pregnancy desire preserve fecundity . 10 . Serious drug hypersensitivity history drug allergy . 11 . Any patient judge investigator unfit participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>